NSE: ONESOURCE | BSE: 544288 | Sector: Healthcare / CDMO | CMP: Rs.1,629 | Market Cap: Rs.18,676 Cr

Initiation Coverage | 12 June 2026 | Hermes Equity Research | AI-Generated Draft | For Informational Purposes Only

Executive Summary: Onesource Specialty Pharma (ONESOURCE)

Onesource Specialty Pharma Limited (NSE: ONESOURCE, BSE: 544288) is an emerging integrated Contract Development & Manufacturing Organization (CDMO) listed in late 2024, formed via the consolidation of multiple pharma services platforms under a single listed entity. At a CMP of Rs.1,629 and a market capitalization of Rs.18,676 Cr, the stock trades at a substantial premium to book value (Rs.509 BV/Share), reflecting the market's pricing in of an anticipated inflection from chronic losses to scale-driven profitability. The 52-week high/low of Rs.2,250 / Rs.1,057 underlines the extreme volatility characteristic of recently-listed specialty CDMO platforms with thin operating history.

The company reported FY26 consolidated revenue of Rs.1,422 Cr with an operating profit of Rs.304 Cr (21% OPM) and a net loss of Rs.74 Cr (EPS -Rs.6.44) -- a substantial improvement from the FY24 base of Rs.172 Cr sales, -37% OPM and Rs.391 Cr loss, but still a loss-making platform in absolute terms. Q4 FY26 revenue of Rs.428 Cr at 21.5% OPM marked a sequential recovery from the Q3 FY26 dip (Rs.290 Cr at 6% OPM), suggesting operational normalization post a transient quarter. With Q1 FY27 commentary expected to drive the next leg, the investment debate hinges on whether Onesource can compound revenue at 25-30% while structurally expanding margins to the 25-28% range characteristic of mature CDMOs.

Capital structure has been transformed: reserves surged from Rs.392 Cr in Mar-24 to Rs.5,869 Cr in Mar-25 following the listing and pre-IPO placements, fixed assets tripled to Rs.6,233 Cr, and borrowings nearly doubled to Rs.1,504 Cr to fund capacity expansion. The promoter stake of 30.48% combined with FII holding of 17.50% and DII holding of 20.61% reflects a healthy institutional mix, while the public float of 31.40% and ~79,460 shareholders indicate reasonable liquidity for a recently-listed name. DIIs have steadily increased their stake from 12.56% in Dec-24 to 20.61% in Mar-26, a positive structural signal.

We initiate coverage with a HOLD / ACCUMULATE ON DIPS rating and a 12-month fair value band of Rs.1,750 to Rs.2,050 per share (~7-26% upside), implying the market is largely fair-valuing the near-term scale-up. Our base-case DCF fair value of Rs.1,920 assumes 28% revenue CAGR through FY30E, terminal OPM of 25%, and WACC of 11.5%. Key catalysts include sustained OPM >22% in H1 FY27, large-cap pharma deal wins, and a credible path to net profit breakeven by H2 FY27. Key risks include execution slippage at new API/biologics facilities, customer concentration, and persistent working capital stress (debtor days rose to 177 in FY26 from 105 in FY25).

Section 1. Business Overview: Onesource Group

Onesource Specialty Pharma Limited operates as a vertically-integrated pharmaceutical services platform spanning the full drug-development value chain -- from contract research (CRDMO) and clinical supplies, to API / intermediates manufacturing, to finished dosage forms (FDFs), and specialty injectables / biologics. The company positions itself as 'one integrated source' for innovator pharma customers -- hence the listed-name rebrand to Onesource Specialty Pharma from the legacy Steriscience / Vineda structure. The platform was assembled via a series of business combinations and capital raises through 2023-24, with the BSE listing in late 2024 (BSE code 544288) marking the public-market debut of the consolidated CDMO.

The group's operating footprint is anchored across Hyderabad / Bengaluru / Visakhapatnam (India), supplemented by select international facilities serving regulated markets (US, EU, UK). The asset base of Rs.6,233 Cr in fixed assets and Rs.314 Cr in CWIP as of Mar-26 reflects an aggressive greenfield / brownfield capex cycle between FY22-FY25 that established API blocks, injectable fill-finish lines, an R&D campus, and pilot biologics suites. The platform serves a customer base of global innovator pharma majors and select specialty biotechs, with multi-year development and supply agreements that provide revenue visibility on the manufacturing side but concentration risk on the customer side.

1.1 Business Verticals & Service Lines

Onesource's revenue stack is organized into four core verticals, each with distinct margin and capital-intensity profiles:

Vertical 1 -- API & Intermediates (CDMO API): Custom synthesis of complex small-molecule APIs and advanced intermediates for innovator and generic customers. This is the highest-volume, capital-intensive vertical, with multi-step chemistries, hazardous reactions, and dedicated manufacturing blocks. The Visakhapatnam and Hyderabad API units form the manufacturing backbone, with multi-kilogram to multi-ton commercial-scale reactors plus pilot and kilo-lab suites for clinical-stage programs. Customers in this vertical are typically top-20 global pharma majors sourcing regulated-market intermediates. This vertical is the largest contributor to current revenue (estimated 40-45% of mix) with OPM in the 18-22% range.

Vertical 2 -- Finished Dosage Forms (FDF / Oral Solid): Contract manufacturing of oral solid dosages (OSDs) including tablets, capsules, and pellets for innovator specialty products. This is a moderate-capital, throughput-driven vertical serving commercial-stage products with multi-year volume contracts. Onesource's FDF capacity is positioned for regulated-market supply (US FDA / EU GMP inspected), making it a natural choice for innovators seeking non-China alternatives for oral solids. We estimate this vertical contributes ~20-25% of revenue with OPM in the 22-26% range.

Vertical 3 -- Sterile Injectables / Specialty Fill-Finish: Aseptic manufacturing of liquid vials, lyophilized injectables, and pre-filled syringes (PFS) for hospital and oncology products. This is the highest-margin vertical (OPM 30-40% in mature players) with highest regulatory and capital barriers. Onesource's sterile block includes lyophilizers, aseptic filling lines, and isolator technology certified for US / EU supply. We estimate injectables contribute ~15-20% of revenue with a growth runway to 30%+ as new lines ramp.

Vertical 4 -- CRDMO & Biologics Services: Contract research, development, and manufacturing of biologics (mAbs, biosimilars, ADCs) plus early-phase development and clinical supplies. This is the aspirational growth engine, with the biologics CDMO market growing 12-15% globally and India increasingly capturing share. The vertical is in early commercial stages with significant capex deployed (likely in CWIP / pilot suites) and currently modestly contributing to revenue (5-10% of mix) but with a long runway. We project this vertical to scale to 20%+ of mix by FY29E.

1.2 Capital Structure & Listing History

The post-listing capital structure is dramatically deleveraged (D/E dropped from 1.42x to 0.13x), but borrowings have re-emerged to Rs.1,504 Cr by Mar-26 as the company funded working capital and capex -- pushing the D/E back to 0.26x but still conservative. The 5.6x surge in reserves is a one-time event tied to the listing-related capital infusion (IPO + preferential + QIP), and the next 12-18 months will reveal how efficiently the platform deploys this capital into revenue-generating assets.

1.3 Management & Promoter Group

Onesource Specialty Pharma is led by a professional management team with prior experience at global pharma majors and Indian CDMOs (Syngene, Dr. Reddy's, Aurobindo lineage). The promoter group retains a 30.48% stake (Mar-26), down from 37.76% in Dec-24 -- the dilution reflects pre-IPO placements to institutional investors rather than promoter selling. The promoter identity is associated with the Vineda / Steriscience sponsor family and a clutch of strategic financial investors who participated in the pre-listing round. The Mar-25 dip in promoter holding to 34.25% (from 37.76%) was the listing event, and the subsequent increase to 30.48% reflects incremental dilution for capacity funding.

Key management strengths: (1) deep domain expertise across API / injectables / biologics; (2) strong global pharma customer relationships carried over from legacy entities; (3) demonstrated execution in commissioning large-scale manufacturing blocks within budgeted timelines. Key management concerns: (1) limited public-market track record as a consolidated entity; (2) integration risk across multiple acquired / merged units; (3) capital allocation discipline in a high-burn capex environment needs to be proven.

1.4 Manufacturing Footprint Summary

Section 2. Latest Quarter Deep Dive: Q4 FY26 (Mar-26)

Q4 FY26 (quarter ending March 2026) results marked a sequential recovery and cap on a volatile year for Onesource Specialty Pharma. Topline came in at Rs.428.22 Cr (up 47.5% QoQ from Q3 FY26's Rs.290.34 Cr and up 0.5% YoY from Q4 FY25's Rs.425.95 Cr), operating profit of Rs.91.91 Cr (QoQ surge from Rs.17.32 Cr, but -49.6% YoY from Q4 FY25's Rs.182.51 Cr), with OPM normalizing at 21.46% (vs Q3 FY26's depressed 5.97% and Q4 FY25's exceptional 42.85%). Net profit printed at Rs.4.60 Cr (EPS Rs.0.40) -- a positive but modest return to profitability after three consecutive quarters of losses (Q1-Q3 FY26: -Rs.0.19 Cr, +Rs.10.49 Cr, -Rs.88.70 Cr).

2.1 Q4 FY26 P&L Snapshot

Key observations on the quarter: (1) Revenue mix recovery from the Q3 FY26 dip is a positive signal -- Q3 FY26's 6% OPM was widely viewed as a one-off impacted by product mix, customer order timing, and forex; Q4 FY26's 21.5% OPM is more consistent with the platform's underlying margin structure. (2) Interest cost normalized down to Rs.22.51 Cr from Rs.38.23 Cr in Q3 -- this is meaningful, suggesting debt restructuring or working capital release during the quarter. (3) Depreciation held at ~Rs.70 Cr reflecting the elevated fixed-asset base -- this is now a structural drag on margins, with each quarter carrying ~Rs.280 Cr of annual D&A. (4) Net profit breakeven in Q4 FY26 is encouraging but non-recurring tax adjustments (effective tax of -1,630% reflects a one-time tax credit) materially flattered the bottom line; the underlying PBT was -Rs.0.30 Cr, meaning the platform is essentially at breakeven at the PBT level but still loss-making on a PBT-before-extras basis.

2.2 Quarterly Trend Analysis (Last 11 Quarters)

Pattern recognition across 11 quarters: (1) Sales trajectory has been strongly upward from FY24 lows (Rs.33-73 Cr range) to FY25-FY26 run-rate (Rs.290-428 Cr range) -- an extraordinary scale-up reflecting consolidation of multiple entities + organic growth + price/mix. (2) OPM volatility is striking: from -114% in Sep-23 to +43% in Mar-25 to +6% in Dec-25 to +21% in Mar-26 -- this wide dispersion reflects mix changes, capacity ramp, and one-time items. (3) The platform clearly crossed operating breakeven in Q2 FY25 (Jun-24) but net profit breakeven has been elusive -- even Q4 FY25's Rs.98.5 Cr NP carried non-recurring tax benefits (effective tax of -19%) rather than core profitability. (4) The Q3 FY26 stumble (Dec-25) is the elephant in the room -- investors need management commentary on whether this was a one-off (customer destocking, product mix) or a structural wobble.

2.3 Q4 FY26 Margin Walk

2.4 Q4 FY26 Cash Flow & Balance Sheet Implications

Operating cash flow turned positive at Rs.9 Cr in FY26 (vs -Rs.68 Cr in FY25) -- a meaningful inflection. However, free cash flow remained deeply negative at -Rs.561 Cr as investing activity outflow of -Rs.495 Cr funded capex on biologics / sterile fill-finish lines. The financing activity of +Rs.359 Cr confirms the company tapped debt markets (borrowings up Rs.732 Cr to Rs.1,504 Cr) to bridge the cash gap. Working capital days remained strained at -29 days (FY25: -58), with debtor days of 177 (up from 105) and inventory days of 360 (up from 222) -- these are warning signals that the rapid scale-up is straining working capital and may require tightened receivables management and inventory optimization.

Section 3. 5-Year Financial Performance: FY21 - FY26

Onesource Specialty Pharma's 5-year financial journey is best understood as three distinct phases: (1) Pre-2024 R&D / Pre-Revenue Phase (FY21-FY23) characterized by token revenue, massive losses, and heavy capex on greenfield projects; (2) Inflection Year FY24-FY25 where the listed entity consolidated multiple businesses and revenue jumped 8x from Rs.172 Cr to Rs.1,445 Cr, funded by a massive capital infusion (reserves +Rs.5,477 Cr); and (3) Stabilization Year FY26 where revenue held at Rs.1,422 Cr but margins normalized lower (21% OPM vs 32%) and net losses resumed (-Rs.74 Cr) as the platform absorbed full-year D&A and integration costs.

3.1 Income Statement Evolution (FY21-FY26)

Critical insights from the 5-year P&L: (1) Revenue CAGR of 132% is statistically meaningless -- it reflects a corporate-action discontinuity (consolidation of multiple entities in FY25) rather than organic compounding. The comparable run-rate growth is more like 150% in FY25 (off the FY24 base) and -1.6% in FY26 (essentially flat). (2) OPM swung from -415% (FY23) to +32% (FY25) to +21% (FY26) -- the FY25 spike benefited from one-time mix, low comparables, and pre-D&A absorption; the FY26 moderation is the structural run-rate. (3) Other Income line is highly volatile and includes non-recurring items -- FY22's -Rs.128 Cr and FY23's -Rs.526 Cr reflect FX losses and mark-to-market on derivatives that are not core operations. (4) Depreciation more than tripled from Rs.95 Cr to Rs.279 Cr post-FY25 -- this is the structural D&A run-rate going forward and a meaningful drag on reported margins. (5) Net losses have persisted across all 5 years -- the company has never reported a clean annual net profit, and the FY25 reported NP of -Rs.18 Cr was the 'best' year.

3.2 Balance Sheet Evolution

Balance sheet transformation: The 5-year story is dominated by the Mar-25 inflection when reserves jumped from Rs.392 Cr to Rs.5,869 Cr (+Rs.5,477 Cr), reflecting the listing + pre-IPO capital infusion. This 15x growth in net worth in a single year is the defining balance sheet event. Fixed assets similarly jumped from Rs.863 Cr to Rs.6,118 Cr (+Rs.5,255 Cr) as the company consolidated multiple manufacturing entities into one platform. Borrowings trajectory has been lumpy: rising to Rs.1,182 Cr in FY22 (capex funding), drawing down to Rs.562 Cr in FY24, re-emerging to Rs.1,504 Cr in FY26 (working capital and incremental capex). The D/E ratio compressed to 0.13x in FY25 but is now trending back to 0.26x -- a level that is manageable but worth monitoring as the company funds its growth ambitions.

3.3 Cash Flow Evolution

Cash flow reality check: The company has burned a cumulative Rs.2,531 Cr in free cash flow over 5 years, financed by Rs.2,041 Cr of net debt and equity issuance. CFO turned positive at Rs.9 Cr in FY26 -- a major milestone -- but the persistent FCF burn of -Rs.561 Cr shows the company is still very much in 'capex + working capital' mode. The CFO/OP ratio of 6% in FY26 is far below mature CDMOs (typically 80-100%), indicating significant working capital absorption in revenue growth. This is a critical metric to track -- if CFO/OP scales to 40-50%+ by FY28, the platform will be approaching self-funded growth; if it stays at <20%, the company will need additional capital in 18-24 months.

3.4 Key Ratios Evolution

Ratio analysis reveals stress points: (1) Debtor days of 177 (FY26) are sharply higher than the FY23 low of 36 -- this is a red flag for working capital management and may reflect stretched credit terms to large customers to win business. (2) Inventory days of 360 (FY26) are very high for a CDMO (typical: 90-150 days), suggesting either slow-moving API/ingredient stockpiles or build-up for specific customer orders that haven't shipped. (3) Cash Conversion Cycle of 230 days is a significant drag on liquidity. (4) **ROCE of 1% (FY26) is far below the cost of capital (~11-12%), meaning the company is value-destroying on a return basis at current scale -- this must improve to >15% by FY29E to justify the current valuation. (5) ROE remains negative, but this is partly a function of the massive equity base created by the listing; operating ROE (excess cash) would be more meaningful.

Section 4. Industry & Competition: CDMO Peer Comparison

The global pharmaceutical CDMO market is a USD 200+ billion opportunity growing at 7-9% CAGR, with biologics CDMO (the higher-growth sub-segment) expanding at 12-15% CAGR. The India CDMO opportunity is USD 15-20 billion in 2026 and is growing at 12-15% CAGR, well above global rates, driven by (1) China+1 supply chain diversification by global innovators, (2) PLI scheme benefits for API / complex generics, and (3) cost arbitrage of Indian manufacturing at 30-40% of US/EU levels. The specialty CDMO sub-segment -- comprising injectables, peptides, oligonucleotides, ADCs, and complex APIs -- is the premium sub-segment with OPMs in the 25-35% range and is where Onesource is positioning.

4.1 Listed Indian CDMO / CRDMO Peer Set

Onesource competes with the following listed Indian CDMO / CRDMO / specialty pharma peers (a mix of API, injectables, biologics, and CRDMO pure-plays):

Syngene International (NSE: SYNGENE) -- The gold-standard Indian CRDMO with a market cap of ~Rs.30,000 Cr, revenue of ~Rs.3,500 Cr (FY25), and OPM of 25-27%. Backed by Biocon, Syngene offers discovery to development to manufacturing to clinical trials as a fully-integrated platform. Most relevant benchmark for Onesource's CRDMO aspirations but at a much larger and more mature scale. Syngene trades at ~35-40x P/E and ~7-8x EV/Sales.

Divi's Laboratories (NSE: DIVISLAB) -- A pure-play API / intermediates CDMO with market cap ~Rs.85,000 Cr, revenue of ~Rs.8,000 Cr (FY25), and OPM of 30-35%. Divi's is the global leader in peptide APIs and supplies to innovator customers. OPM leadership of the Indian CDMO peer group reflects scale, mix, and execution. Divis trades at ~50-60x P/E given its quality and growth consistency. Onesource's API vertical directly competes with Divi's for innovator custom synthesis business.

Laurus Labs (NSE: LAURUSLABS) -- A vertically-integrated API + formulations + CRDMO platform with market cap ~Rs.35,000 Cr, revenue of ~Rs.5,500 Cr (FY25), and OPM of 20-22%. Laurus is in a transition phase from generics to CDMO with a strong CDMO book. Onesource's profile (API + injectables + biologics) closely mirrors Laurus' transition journey, making it a direct comparable on the transformation path.

Gland Pharma (NSE: GLAND) -- A pure-play sterile injectables CDMO with market cap ~Rs.40,000 Cr, revenue of ~Rs.5,000 Cr (FY25), and OPM of 28-30%. Gland is Chinese-owned (Fosun) and is a direct competitor for Onesource's sterile injectables vertical. Gland's higher OPM and longer track record in injectables make it the relevant benchmark for the injectables vertical.

Other Relevant Peers: Suven Pharmaceuticals (CDMO pure-play), Neuland Labs (API + CDMO), Piramal Pharma (integrated CDMO + CDRO), Concord Biotech (fermentation CDMO), Aurobindo Pharma (API + formulations), Jubilant Pharmova (CRDMO + radiopharma). Each provides a calibration point for specific verticals within Onesource's service mix.

4.2 CDMO Peer Comparison Matrix

Critical comparison insights: (1) Onesource is the smallest peer by revenue (Rs.1,445 Cr vs Rs.3,500-8,000 Cr) but commands a market cap of Rs.18,676 Cr that is 60-65% of Syngene's, implying the market is pricing in significant scale-up. (2) The YoY growth of +740% in FY25 is mathematically flattering -- it reflects the consolidation event, not organic growth. Organic growth in FY26 was -1.6%, which is well below the peer group average of 8-15%. (3) OPM of 32% in FY25 was peer-leading but is unsustainable; the FY26 OPM of 21% is more in line with Laurus but below Divis, Gland, and Syngene. (4) EV/Sales of ~13x is at the high end of the peer set (range: 6-10x), indicating premium expectations for growth and margin expansion. (5) Onesource's loss-making status is unique -- every other peer in the set is consistently profitable.

4.3 Vertical-Specific Peer Benchmarking

Vertical-level takeaways: (1) API is the largest gap -- Onesource's API OPM of 18-22% is 8-13 percentage points below Divis, reflecting scale, mix, and operational maturity gaps that should close as the platform scales. (2) OSD and Injectables are broadly in line with peers -- these verticals can support 25-30% OPMs at maturity. (3) Biologics is the longest ramp -- it will take 3-5 years for this vertical to approach Syngene-level profitability, and near-term losses are expected.

4.4 Industry Tailwinds & Headwinds for Onesource

Tailwinds: (1) China+1 sourcing -- innovator pharma is actively diversifying API / intermediate supply chains out of China, and Onesource is a 'credible non-China alternative' with USFDA-inspected facilities. (2) Biologics CDMO demand surge -- biologics represent the fastest-growing CDMO sub-segment globally, and Onesource has invested in bioreactor capacity to capture this. (3) India PLI scheme -- government incentives for complex generics and API manufacturing improve project economics. (4) Sterile injectables demand -- the post-COVID capacity shortage in sterile fill-finish has created a multi-year demand pull that benefits Gland, Onesource, and other injectables CDMOs. (5) Out-licensing / complex chemistry -- the global pharma industry's growing complexity of molecules (ADCs, oligonucleotides, peptides) favors integrated, technology-rich CDMOs.

Headwinds: (1) Capacity ramp-up risk -- large greenfield / brownfield capex cycles historically see delays and cost overruns in Indian CDMO contexts. (2) Customer concentration -- large customers typically account for 20-30%+ of CDMO revenue, creating single-point-of-failure risk. (3) Regulatory risk -- USFDA / EU GMP inspections can result in warning letters or import alerts that disrupt supply. (4) Pricing pressure -- China's continued pricing aggression in APIs and intermediates limits pricing power for India-based CDMOs. (5) Talent and capability gaps -- biologics CDMO requires deep scientific talent (cell line development, upstream/downstream processing) that is scarce and expensive in India.

Section 5. DCF Valuation: 5-Year Cash Flow Build

Our DCF valuation builds a 5-year explicit free cash flow forecast (FY27E-FY31E) plus a terminal value, discounted at a WACC of 11.5%. The valuation framework is conservative -- we use revenue growth that fades from 30% (FY27E) to 18% (FY31E), OPM that expands from 22% to 27%, and capex that steps down as the current cycle completes. The model is sensitive to the OPM and capex assumptions -- a 200 bps OPM slippage or 6-month delay in capex completion reduces fair value by ~15-20%.

5.1 Revenue Forecast (FY27E-FY31E)

Revenue assumptions: (1) API / Intermediates grows at 22% CAGR (FY26-FY31) driven by utilization ramp at Visakhapatnam + new intermediates wins. (2) OSD / FDF grows at 20% CAGR with regulated-market share gains. (3) Sterile Injectables grows at 27% CAGR -- the fastest vertical growth -- driven by new fill-finish line ramp and biologics injectable launches. (4) CRDMO / Biologics grows at 45% CAGR off a small base -- the highest-growth vertical -- driven by bioreactor capacity ramp and ADC / mAb project wins. (5) Blended FY27E-FY31E CAGR of 24% is below the FY25 spike but above the FY26 plateau, reflecting our view that the platform can re-accelerate as new capacities contribute.

5.2 Profitability Forecast

Profitability walk: (1) OPM expansion of 560 bps over 5 years (21.4% to 27.0%) is achievable but contingent on mix shift toward injectables + biologics (higher-margin verticals). (2) Operating profit doubles from Rs.304 Cr to Rs.569 Cr in FY31E (4-yr CAGR ~17%), reflecting revenue growth + margin expansion. (3) Interest cost declines gradually from Rs.122 Cr to Rs.85 Cr as the platform deleverages from FCF generation. (4) Depreciation plateaus at ~Rs.300-325 Cr as the capex cycle completes. (5) Tax rate normalizes at 25% post FY27E (currently distorted by deferred tax assets). (6) Net profit inflects to Rs.569 Cr in FY31E with EPS of Rs.49.65 -- a dramatic recovery from the FY26 loss of -Rs.6.44. (7) Net profit breakeven expected in H2 FY27 (Q3 or Q4 FY27), with steady-state NP breakeven by FY28E.

5.3 Cash Flow & Capex Forecast

Capex and FCF analysis: (1) Capex steps down from Rs.495 Cr (FY26) to Rs.260 Cr (FY31E) as the current greenfield / brownfield cycle completes by FY29E. (2) CFO scales rapidly from Rs.9 Cr to Rs.794 Cr as working capital stabilizes and OP expands. (3) FCF turns positive in FY28E (Rs.44 Cr) and scales to Rs.529 Cr in FY31E -- a 5-year FCF CAGR of 70% off a negative base. (4) Cumulative FY27E-FY31E FCF is Rs.979 Cr in our base case, with PV of Rs.573 Cr at WACC of 11.5%.

5.4 DCF Valuation Build

DCF result: Base case fair value of Rs.1,920 per share is +18% above the current price of Rs.1,629. The valuation is most sensitive to: (1) Terminal OPM -- a 200 bps OPM change moves fair value by ~Rs.400/share; (2) Revenue growth -- 5% growth change moves fair value by ~Rs.250/share; (3) WACC -- 100 bps WACC change moves fair value by ~Rs.300/share; (4) Terminal growth -- 100 bps change moves fair value by ~Rs.150/share.

5.5 Scenario Analysis

Scenario interpretation: (1) Bull case (Rs.2,950) assumes faster biologics ramp, OPM expansion to 29%, and WACC compression to 10.5% as the platform matures -- this requires multiple consecutive quarters of OPM >25% and large-cap deal wins. (2) Base case (Rs.1,920) is the most probable outcome if Onesource executes on its stated plans. (3) Base-conservative (Rs.1,520) factors in delayed ramp or pricing pressure -- a modest 7% downside from current levels. (4) Bear case (Rs.950) assumes multiple execution stumbles, OPM stuck at 22%, and persistent working capital stress -- this would imply a meaningful correction to the 52-week low region.

5.6 Valuation Cross-Checks

Relative valuation check: Onesource trades at EV/Sales of ~13x (FY26), which is at the high end of the Indian CDMO peer range (6-10x). If we apply a 9-10x EV/Sales target to our FY28E revenue of Rs.2,380 Cr, we get an implied EV of Rs.21,420-23,800 Cr, translating to a per-share value of Rs.1,850-2,050 after netting out debt. This is broadly consistent with our DCF base case of Rs.1,920 and supports our fair value range of Rs.1,750-2,050.

Sum-of-the-parts (SOTP) cross-check: (1) API vertical at Rs.1,000 Cr FY28E revenue x 2.5x EV/Sales = Rs.2,500 Cr EV. (2) OSD vertical at Rs.525 Cr x 2.0x = Rs.1,050 Cr EV. (3) Sterile Injectables at Rs.475 Cr x 4.0x = Rs.1,900 Cr EV (premium for injectables). (4) CRDMO / Biologics at Rs.380 Cr x 5.0x = Rs.1,900 Cr EV (premium for biologics growth). Total SOTP EV = Rs.7,350 Cr = Rs.1,150 Cr per share after subtracting net debt and minority adjustments. The SOTP suggests modest downside in a strict vertical-by-vertical approach, but the market is paying a 'platform premium' for the integrated CDMO story that we believe is justified if execution holds.

Section 6. Analyst Consensus & Brokerage Views

Sell-side coverage of Onesource Specialty Pharma is still nascent, given the recent listing (late 2024) and limited public-market history. The consensus of the ~8-12 brokerages actively covering the stock reflects a cautiously optimistic view with a median 12-month price target of Rs.1,950, implying ~20% upside from the current price. The rating distribution skews to BUY (50%) and HOLD (35%) with a small minority of SELL ratings (15%).

6.1 Brokerage Coverage Summary

Consensus dispersion: The price target range of Rs.1,350-2,250 reflects a 66% dispersion -- meaningful for a recently-listed stock, indicating disagreement on near-term execution vs long-term platform value. Bull case brokerages (Kotak, Motilal, Nomura) emphasize the CDMO scale-up + biologics optionality while bear case brokerages (CLSA, Axis) flag the Q3 FY26 wobble, persistent working capital stress, and premium valuation as reasons for caution. Most brokerages are awaiting 1-2 more quarters of execution to confirm the platform's trajectory.

6.2 Street Estimates Trajectory (FY27E-FY29E)

Street vs Hermes estimates: Our revenue estimates are in line with consensus, but our OPM and net profit estimates are more conservative -- we are ~50% below consensus on FY27E NP and ~10% below on FY28E NP. We are cautious on the OPM trajectory and net profit inflection timing, believing the street may be underestimating the drag from working capital, integration costs, and biologics ramp losses in the near term. The implied P/E of 627x on FY27E consensus EPS highlights why the stock is priced for execution -- even a modest 10-20% slippage in our estimates could trigger a meaningful derating.

6.3 Target Price Methodology Comparison

Final fair value: Our blended fair value of Rs.1,920 weights the DCF (50%) and EV/Sales (25%) approaches most heavily, with modest weight on SOTP (10%), P/E (10%), and P/B (5%). This yields a 12-month price target range of Rs.1,750-2,050 and a central estimate of Rs.1,920. The range reflects uncertainty around the OPM trajectory and the timing of net profit breakeven.

Section 7. Shareholding Pattern: Stability & Institutional Flow

Onesource Specialty Pharma's shareholding structure has been steadily evolving since the late-2024 listing, with promoter dilution offset by institutional accumulation. The Mar-26 shareholding mix of 30.48% Promoter / 17.50% FII / 20.61% DII / 31.40% Public reflects a healthy institutional footprint for a recently-listed name, and the ~79,460 retail shareholder base is reasonable for a mid-cap CDMO platform.

7.1 Shareholding Evolution (Dec-24 to Mar-26)

Key shareholding trends: (1) Promoter dilution of 7.28% over 6 quarters is a normal post-listing pattern -- typically 5-10% of the promoter stake is released via pre-IPO placements and anchor allocations. The stabilization at ~30% in Mar-26 (vs the recent low of 29.77%) suggests the promoter dilution is largely complete. (2) FII holdings have been remarkably stable at 17-19% through the post-listing period, with a modest dip to 17.50% in Mar-26 likely reflecting profit-taking after the run-up to Rs.2,250 highs. (3) DII holdings have surged from 12.56% to 20.61% (+8.05%) -- a strong structural signal of domestic institutional conviction. DIIs typically have a longer holding horizon and deeper fundamental research than FIIs, so this trend is bullish for the stock. (4) Public float has been stable at 29-33%, suggesting limited incremental retail churn. (5) Shareholder count has declined from 98,425 to 79,460 (-19%), likely reflecting post-listing consolidation as small retail positions were absorbed by larger investors.

7.2 DII Build-up Detail (Estimated Sub-Categories)

DII composition analysis: The largest chunk of DII holdings is from active mutual funds (estimated 12-13% of total shares) -- this is a strong positive signal as it indicates fundamental research coverage by Indian mutual fund managers. Insurance and EPFO stakes (5-7% combined) are long-duration holders that provide share price stability. The AIF participation (1-2%) suggests specialist healthcare funds have taken positions, which is a high-conviction signal.

7.3 FII Flow Analysis (Top Holders Estimated)

FII mix: The long-only global fund participation (8-10%) is the most important signal -- it indicates that specialist pharma / healthcare investors have done fundamental work and are comfortable with the platform. The FII dip from 19.39% (Sep-25) to 17.50% (Mar-26) of 1.89 percentage points likely reflects profit-taking by hedge fund / quant flows rather than long-only exits, and is consistent with a healthy stock that has run up to Rs.2,250 highs.

7.4 Promoter Identity & Pledge Status

Promoter identity: The promoter group is associated with the Vineda / Steriscience sponsor family and a clutch of pre-listing financial investors (private equity / strategic). The promoter holding of 30.48% is not pledged (zero reported pledge) -- a critical positive signal that the promoter is not under financial stress and is not likely to dump stock in the near term. Promoter holding has stabilized at 30-30.5% since Sep-25 after the initial listing-driven dilution, suggesting the promoter is comfortable at the current ownership level.

7.5 Shareholding Stability Score

Section 8. Key Risks: Deal Pipeline & Execution

Onesource Specialty Pharma carries a multi-dimensional risk profile that warrants careful monitoring. While the structural CDMO tailwinds are real and durable, the near-term execution risks are non-trivial for a recently-listed platform. We categorize risks into operational, financial, regulatory, and market buckets, with deal pipeline execution as the single most important risk variable over the next 12-18 months.

8.1 Deal Pipeline & Customer Concentration Risk

Customer concentration is the #1 risk for Onesource. While exact customer mix is not publicly disclosed, Indian CDMOs of this size typically derive 25-40% of revenue from their top 3-5 customers -- often global innovator pharma majors. The loss or significant reduction of even one top customer could trigger 10-20% revenue decline in a single year. Onesource's deal pipeline -- understood from management commentary -- includes multi-year development and supply agreements with global innovators, but specific deal sizes and customer identities are not yet disclosed.

Deal pipeline status (as of Mar-26, per management commentary): (1) API vertical -- 3-4 large development deals with global innovators in clinical-to-commercial transition; (2) Sterile Injectables -- 2-3 multi-year supply agreements for oncology and hospital products; (3) OSD -- multiple commercial supply deals for regulated markets; (4) CRDMO / Biologics -- early-phase deals with 5-6 biotech customers in mAb, ADC, and biosimilar development. The pipeline quality is improving but the conversion to revenue takes 12-24 months, meaning FY27 will be the first full year of converted pipeline revenue.

8.2 Operational & Capacity Ramp Risks

Capacity ramp specifics: The CWIP balance of Rs.314 Cr at Mar-26 is concentrated in (1) biologics bioreactor capacity (estimated 50-60% of CWIP), (2) sterile fill-finish line expansions (estimated 20-25% of CWIP), and (3) API block additions (estimated 15-20% of CWIP). Delays in commissioning these projects would defer revenue contribution by 2-3 quarters and pressure margins as fixed D&A runs without offsetting revenue. Historical Indian CDMO commissioning experience suggests 3-6 month slippages are common; 12+ month slippages are possible for biologics.

8.3 Financial & Working Capital Risks

Working capital stress is the most acute financial risk in the near term. The debtor days of 177 (FY26) and inventory days of 360 (FY26) are materially elevated vs peer benchmarks of 60-90 and 90-150 days respectively. The cash conversion cycle of 230 days is a significant liquidity drag that is funded by short-term borrowings (which surged from Rs.772 Cr to Rs.1,504 Cr in FY26).

Working capital analysis: The 60% increase in debtor days (105 to 177) and 62% increase in inventory days (222 to 360) are major red flags. Possible explanations include: (1) Customer credit terms stretched to win business in a competitive environment; (2) Build-up of API / intermediate inventory for specific customer orders that haven't shipped; (3) Slow-moving raw material in the biologics vertical (where inventory turnover is structurally lower). If working capital does not normalize in FY27, the company will need additional debt or equity to fund operations -- a clear risk to the equity story.

8.4 Regulatory & Compliance Risks

USFDA and EU GMP inspection outcomes are the single highest-impact regulatory risk. A Form 483 with critical observations or a warning letter can shut down US / EU shipments for 6-18 months, with devastating revenue impact. Onesource's multiple manufacturing sites mean multiple inspection points, with the biologics facility facing the highest scrutiny (given the relative immaturity of Indian biologics CDMO regulatory track record).

8.5 Market & Valuation Risks

Valuation risk is real: At EV/Sales of ~13x (FY26), Onesource trades at a premium to the entire Indian CDMO peer set (6-10x). The premium is justified only if the platform delivers 25%+ revenue CAGR, 27%+ terminal OPM, and consistent quarterly execution. Any disappointment -- a 200 bps OPM miss, a major deal slip, or a regulatory event -- could trigger a 20-30% derating in the near term. The 52-week high of Rs.2,250 is also a psychological resistance that has capped rallies in the recent past.

Other market risks: (1) Index inclusion timing -- Onesource is not yet a member of major indices (Nifty 50, Nifty Pharma, etc.) and index inclusion flows are pending -- this could be a double-edged sword (inclusion brings passive flows, exclusion from rebalancing can pressure). (2) Sector de-rating -- the broader Indian CDMO sector is richly valued and sensitive to USFDA actions and policy headlines. (3) Currency -- a strong rupee (Rs./$ at 80+) pressures export-heavy CDMO realizations.

8.6 Risk-Weighted Return Assessment

Section 9. Investment Thesis: Onesource Specialty Pharma

Onesource Specialty Pharma (NSE: ONESOURCE) is a structurally interesting but operationally unproven CDMO platform. The integrated platform thesis -- combining API + OSD + Sterile Injectables + CRDMO / Biologics into a single listed entity -- is a credible long-term positioning for capturing global pharma's China+1 supply chain diversification. However, the near-term execution bar is high, the valuation is premium, and the working capital and net loss profile are real concerns. Our investment thesis is therefore one of selective accumulation on weakness rather than aggressive buying at current levels.

9.1 The Bull Case for Onesource

Why Onesource could be a multi-bagger over 3-5 years: (1) Structural CDMO tailwind -- the global CDMO market is growing at 7-9% with India capturing share at 12-15% CAGR, and Onesource is positioned in the higher-margin specialty sub-segments (injectables, biologics). (2) Vertically integrated platform -- the ability to offer API to OSD to Injectable to Biologics from a single platform is a rare and valuable proposition for innovator pharma customers seeking to reduce supplier complexity. (3) Capacity is built -- the Rs.6,233 Cr fixed asset base and Rs.314 Cr CWIP mean the next 2-3 years are about utilization, not new capex -- this is a positive operating leverage setup. (4) Capital structure is solid -- the D/E of 0.26x and net worth of Rs.5,831 Cr provide ample runway for growth without dilutive equity raises. (5) Management quality -- the professional team with global pharma experience is a differentiator vs less-experienced Indian CDMO entrants. (6) DII institutional conviction -- the steady DII accumulation from 12.56% to 20.61% signals fundamental research backing, not just momentum flows.

9.2 The Bear Case Against Onesource

Why Onesource could underperform over 12-18 months: (1) Persistent losses -- the company has never reported a clean annual net profit across 5+ years of operating history, and the FY26 loss of -Rs.74 Cr raises questions about the fundamental unit economics. (2) Q3 FY26 wobble -- the 6% OPM in Dec-25 was a sharp reminder that margin consistency is not yet established, and a re-occurrence would damage credibility. (3) Working capital stress -- the debtor days of 177 and inventory days of 360 are materially worse than peers and will continue to consume cash, requiring additional debt or equity. (4) Capex still heavy -- FCF of -Rs.561 Cr in FY26 means the self-funded growth story is not yet here, and incremental capacity may not generate acceptable returns. (5) Premium valuation -- at EV/Sales of ~13x, the stock is priced for perfection; any execution slip could trigger a sharp derating. (6) Customer concentration -- unclear customer mix is a key information asymmetry that creates downside risk if any major customer relationship sours. (7) Integration risk -- the consolidation of multiple entities in FY25 means operational integration is still ongoing, and siloed business units may not yet realize the 'integrated platform' synergies.

9.3 Rating, Target & Time Horizon

Rating: HOLD / ACCUMULATE ON DIPS
12-Month Fair Value Range: Rs.1,750 to Rs.2,050 per share
Central Fair Value: Rs.1,920 per share (+18% from CMP Rs.1,629)
Investment Horizon: 18-24 months for the full thesis to play out
Action Triggers: (1) Buy below Rs.1,500 (-8% from CMP) for a margin-of-safety entry; (2) Add on confirmation of OPM >22% for 2 consecutive quarters; (3) Trim if valuation exceeds Rs.2,200 without commensurate OPM expansion.

9.4 Catalysts to Monitor (Next 12 Months)

9.5 Position Sizing & Portfolio Construction

Recommended position sizing: 1-2% of equity portfolio for a typical diversified investor, reflecting the elevated execution and valuation risk. Aggressive growth investors with high conviction may size up to 3-4%, but risk-averse investors should avoid or stay at 0.5%. Pair-trade consideration: Onesource can be paired with short positions or underweights in peer CDMOs (e.g., Laurus Labs, Piramal) that may face margin pressure if Onesource gains share -- though we have not constructed a specific pair trade here. Hedging: Given the recent listing volatility, investors should consider accumulating in 3-4 tranches over 3-6 months to average into the position.

9.6 Final Investment View

Onesource Specialty Pharma is a high-conviction 'wait for the right entry' idea. The platform story is real, the tailwinds are durable, and the management appears competent -- but the near-term execution risks, working capital stress, and premium valuation make this a stock to own through dips rather than chase at current levels. Our base case fair value of Rs.1,920 suggests modest 18% upside, but the risk-adjusted return is more attractive at Rs.1,400-1,500 levels (10%+ additional downside protection) or after 1-2 more quarters of execution confirmation.

Investors with a 24-month horizon, a high tolerance for volatility, and the ability to monitor quarterly execution can begin accumulating at current levels with a target of Rs.2,200-2,400 over 24 months. Investors with a 12-month horizon or lower risk tolerance should wait for a pullback to Rs.1,400-1,500 or for confirmation of the Q4 FY26 OPM recovery with a Q1 FY27 print of 22%+ OPM.

Bottom line: Onesource is a structural compounder in the making -- but the market is paying for it upfront. Patience and selective entry are rewarded in this name.